DUBLIN--(BUSINESS WIRE)--The "Opioid Receptor Antagonists- Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
"Opioid Receptor Antagonists- Pipeline Insight, 2018" report outlays comprehensive Insight of present scenario and growth prospects across Opioid Receptor Antagonists. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 30+ products along with 20+ companies involved.
Products covered by Phase
- Phase III, Phase II and Phase I
- Pre-clinical and Discovery
- Inactive (Dormant and Discontinued)
Overview of pipeline development activities for Opioid Receptor Antagonists
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Opioid Receptor Antagonists
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.
- Adolor Corporation
- Astraea Therapeutics
- BlackThorn Therapeutics
- Eli Lilly
- INSYS Therapeutics
- Janssen Pharmaceuticals
- Japan Tobacco
- Kyorin Pharmaceuticals
- Opiant Pharmaceuticals
- RTI International
- SRI International
- TaiwanJ Pharmaceuticals
- Theravance Biopharma
- Trevi Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/dbk854/opioid_receptor?w=4